Show simple item record

dc.contributor.authorMoiseyenko, V
dc.contributor.authorSaunders, Mark P
dc.contributor.authorWasan, HS
dc.contributor.authorArgiles, G
dc.contributor.authorBorg, C
dc.contributor.authorCreemers, GJ
dc.contributor.authorFedyanin, M
dc.contributor.authorGlynne-Jones, R
dc.contributor.authorPfeiffer, P
dc.contributor.authorPunt, CJA
dc.contributor.authorStroyakovskiy, D
dc.contributor.authorTen Tije, AJ
dc.contributor.authorde Wouw, AWV
dc.contributor.authorKanehisa, A
dc.contributor.authorFougeray, R
dc.contributor.authorSabater, J
dc.contributor.authorAmellal, N
dc.contributor.authorVan Cutsem, E
dc.date.accessioned2019-11-19T16:01:10Z
dc.date.available2019-11-19T16:01:10Z
dc.date.issued2019en
dc.identifier.citationMoiseyenko V, Saunders MP, Wasan HS, Argiles G, Borg C, Creemers G-J, et al. QoL from TASCO1: health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy�Results from the TASCO1 phase II study. J Clin Oncol. 2019;37(4_suppl):676-.en
dc.identifier.doi10.1200/JCO.2019.37.4_suppl.676en
dc.identifier.urihttp://hdl.handle.net/10541/622482
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.4_suppl.676en
dc.titleQoL from TASCO1: health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy-Results from the TASCO1 phase II studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentClinical and Research Center of Specialized Types of Medical Care (Oncological), St. Petersburgen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record